
VERU
USDVeru Inc. Common Stock
即時價格
價格圖表
關鍵指標
市場指標
開盤
$2.580
最高
$2.650
最低
$2.580
交易量
0.18M
公司基本面
市值
42.5M
行業
生物科技
國家
United States
交易統計
平均交易量
0.18M
交易所
NCM
貨幣
USD
52週範圍
AI分析報告
最後更新: 2025年11月10日VERU Stock Analysis: Veru Inc. Navigates Volatility Amid Fundamental Challenges
Market Snapshot
Current Price: $2.61 (as of 2025-11-10) 52-Week Range: $2.42 - $14.20 Market Cap: $41.89M | P/E Ratio: -9.00 Recent Volatility: Sharp decline from $4.43 (Oct 20) to $2.61, with erratic volume patterns
Recent Performance: Turbulent Descent
Veru’s stock has been in a clear downtrend since mid-October, shedding 41% from its October peak. Key observations:
- Public Offering Impact: The $25M offering on Oct 30 likely triggered selling pressure, with shares dropping 12% the following day.
- Volume Anomalies: Unusually high trading volume on Oct 30 ($765,700) and Nov 3 ($489,500) suggests panic selling or institutional exits.
- Support Zone: Recent closes near $2.52-$2.58 align with its 52-week low, indicating this range may act as temporary support.
Technical Signals: Mixed Messages
- Bullish DMI: +DI (15.4) > -DI (14.1) with ADX at 19.0 implies a weak uptrend could form if buyers step in.
- Volume Surge: 1.9x average volume on Nov 10 hints at renewed interest, but this could reflect short-term positioning rather than sustainable demand.
- MACD Death Cross: Bearish momentum confirmed as MACD (0.0119) fell below signal line (0.0162) despite AI’s upward projections.
Fundamentals: Value Trap or Hidden Potential?
- Contradictory Valuation: While the P/E (-9.00) appears broken due to negative earnings, the recommendation claims it’s “0.4x industry average” (likely referencing EBITDA multiples or forward estimates). Proceed with skepticism.
- **High-Risk
相關新聞
Veru to Present Two Abstracts at ObesityWeek 2025
MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
Veru Announces Pricing of $25 Million Public Offering
MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory
AI預測Beta
AI推薦
更新於: 2025年11月10日 下午02:42
58.4% 信心度
風險與交易
入場點
$2.52
獲利了結
$2.61
止損
$2.30
關鍵因素
相關股票
保持更新
設定價格提醒,獲取AI分析更新和即時市場新聞。